Suggested remit - To appraise the clinical and cost effectiveness of treosulfan with fludarabine within its marketing authorisation as a conditioning treatment for non-malignant diseases prior to allogeneic haematopoietic stem cell transplantation.
Status Awaiting development
Decision None selected
Process TA
ID number 1540

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
09 December 2019 Following the scoping exercise this topic was not referred to NICE for a Technology Appraisal. The block scoping report containing this topic is published here; (Batch 65)
24 January 2019 - 21 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual